


# Clinical iPSC Platform for Cell Therapy Development

From Donor-qualified iPSCs to GMP Master Cell Banks & Cell Therapy Manufacturing

REPROCELL's StemRNA™ Clinical iPSCs provide a robust, regulatory-aligned starting material for cell therapy development—from preclinical studies to early clinical programs.

Selected clones from this platform have already advanced to Phase 3 trials.

## Our Clinical Stem Cell Project Workflow



### StemRNA

Clinical iPSC Platform

- **Footprint-free** StemRNA reprogramming
- **Donor-screened** starting material
- **Clinical Seed Clones** for GMP MCB/WCB generation
- **Pilot Clones** for evaluation & process development
- **Custom Seed iPSCs**, matching your donor criteria

### StemEdit

AI-Driven Gene Editing

- Precise gene edits
- No commercial license
- Optimized for research & clinical

### GMP Manufacturing & Regulatory Support

- GMP Master & Working Cell Bank generation in Europe & US
- Cell therapy manufacturing support
- IND / IMPD-enabling documentation
- FDA / EMA / PMDA-aligned processes
- Active FDA Drug Master File

## Why Cell Therapy Developers Choose REPROCELL

- ✓ **One-stop shop** for iPSC solutions, from research to clinical programs
- ✓ **All donors consented** for commercial and clinical use
- ✓ **Extensive QC** at every manufacturing step ensures compliance with **FDA, EMA, PMDA**
- ✓ **Footprint-free RNA reprogramming** – no vector retention
- ✓ **Evaluation phase** allows selection of best iPSC clone prior to GMP manufacturing
- ✓ **Simple licensing**: StemRNA reprogramming – one-time license; StemEdit – no license

